BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 24445817)

  • 1. PU.1 is essential for MLL leukemia partially via crosstalk with the MEIS/HOX pathway.
    Zhou J; Wu J; Li B; Liu D; Yu J; Yan X; Zheng S; Wang J; Zhang L; Zhang L; He F; Li Q; Chen A; Zhang Y; Zhao X; Guan Y; Zhao X; Yan J; Ni J; Nobrega MA; Löwenberg B; Delwel R; Valk PJ; Kumar A; Xie L; Tenen DG; Huang G; Wang QF
    Leukemia; 2014 Jul; 28(7):1436-48. PubMed ID: 24445817
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PBX3 and MEIS1 Cooperate in Hematopoietic Cells to Drive Acute Myeloid Leukemias Characterized by a Core Transcriptome of the MLL-Rearranged Disease.
    Li Z; Chen P; Su R; Hu C; Li Y; Elkahloun AG; Zuo Z; Gurbuxani S; Arnovitz S; Weng H; Wang Y; Li S; Huang H; Neilly MB; Wang GG; Jiang X; Liu PP; Jin J; Chen J
    Cancer Res; 2016 Feb; 76(3):619-29. PubMed ID: 26747896
    [TBL] [Abstract][Full Text] [Related]  

  • 3. p27kip1 maintains a subset of leukemia stem cells in the quiescent state in murine MLL-leukemia.
    Zhang J; Seet CS; Sun C; Li J; You D; Volk A; Breslin P; Li X; Wei W; Qian Z; Zeleznik-Le NJ; Zhang Z; Zhang J
    Mol Oncol; 2013 Dec; 7(6):1069-82. PubMed ID: 23988911
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Persistent transactivation by meis1 replaces hox function in myeloid leukemogenesis models: evidence for co-occupancy of meis1-pbx and hox-pbx complexes on promoters of leukemia-associated genes.
    Wang GG; Pasillas MP; Kamps MP
    Mol Cell Biol; 2006 May; 26(10):3902-16. PubMed ID: 16648484
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MiR-495 is a tumor-suppressor microRNA down-regulated in MLL-rearranged leukemia.
    Jiang X; Huang H; Li Z; He C; Li Y; Chen P; Gurbuxani S; Arnovitz S; Hong GM; Price C; Ren H; Kunjamma RB; Neilly MB; Salat J; Wunderlich M; Slany RK; Zhang Y; Larson RA; Le Beau MM; Mulloy JC; Rowley JD; Chen J
    Proc Natl Acad Sci U S A; 2012 Nov; 109(47):19397-402. PubMed ID: 23132946
    [TBL] [Abstract][Full Text] [Related]  

  • 6. GSK-3 promotes conditional association of CREB and its coactivators with MEIS1 to facilitate HOX-mediated transcription and oncogenesis.
    Wang Z; Iwasaki M; Ficara F; Lin C; Matheny C; Wong SH; Smith KS; Cleary ML
    Cancer Cell; 2010 Jun; 17(6):597-608. PubMed ID: 20541704
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hoxa9 and Meis1 are key targets for MLL-ENL-mediated cellular immortalization.
    Zeisig BB; Milne T; García-Cuéllar MP; Schreiner S; Martin ME; Fuchs U; Borkhardt A; Chanda SK; Walker J; Soden R; Hess JL; Slany RK
    Mol Cell Biol; 2004 Jan; 24(2):617-28. PubMed ID: 14701735
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Linkage of the potent leukemogenic activity of Meis1 to cell-cycle entry and transcriptional regulation of cyclin D3.
    Argiropoulos B; Yung E; Xiang P; Lo CY; Kuchenbauer F; Palmqvist L; Reindl C; Heuser M; Sekulovic S; Rosten P; Muranyi A; Goh SL; Featherstone M; Humphries RK
    Blood; 2010 May; 115(20):4071-82. PubMed ID: 20237320
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pbx3 and Meis1 cooperate through multiple mechanisms to support Hox-induced murine leukemia.
    Garcia-Cuellar MP; Steger J; Füller E; Hetzner K; Slany RK
    Haematologica; 2015 Jul; 100(7):905-13. PubMed ID: 25911551
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dimerization of MLL fusion proteins immortalizes hematopoietic cells.
    Martin ME; Milne TA; Bloyer S; Galoian K; Shen W; Gibbs D; Brock HW; Slany R; Hess JL
    Cancer Cell; 2003 Sep; 4(3):197-207. PubMed ID: 14522254
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Deregulation of the HOXA9/MEIS1 axis in acute leukemia.
    Collins CT; Hess JL
    Curr Opin Hematol; 2016 Jul; 23(4):354-61. PubMed ID: 27258906
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MEIS1 regulates an HLF-oxidative stress axis in MLL-fusion gene leukemia.
    Roychoudhury J; Clark JP; Gracia-Maldonado G; Unnisa Z; Wunderlich M; Link KA; Dasgupta N; Aronow B; Huang G; Mulloy JC; Kumar AR
    Blood; 2015 Apr; 125(16):2544-52. PubMed ID: 25740828
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Initiation of MLL-rearranged AML is dependent on C/EBPα.
    Ohlsson E; Hasemann MS; Willer A; Lauridsen FK; Rapin N; Jendholm J; Porse BT
    J Exp Med; 2014 Jan; 211(1):5-13. PubMed ID: 24367003
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PBX3 is essential for leukemia stem cell maintenance in MLL-rearranged leukemia.
    Guo H; Chu Y; Wang L; Chen X; Chen Y; Cheng H; Zhang L; Zhou Y; Yang FC; Cheng T; Xu M; Zhang X; Zhou J; Yuan W
    Int J Cancer; 2017 Jul; 141(2):324-335. PubMed ID: 28411381
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Meis1 is an essential and rate-limiting regulator of MLL leukemia stem cell potential.
    Wong P; Iwasaki M; Somervaille TC; So CW; Cleary ML
    Genes Dev; 2007 Nov; 21(21):2762-74. PubMed ID: 17942707
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The AAA+ ATPase RUVBL2 is a critical mediator of MLL-AF9 oncogenesis.
    Osaki H; Walf-Vorderwülbecke V; Mangolini M; Zhao L; Horton SJ; Morrone G; Schuringa JJ; de Boer J; Williams O
    Leukemia; 2013 Jul; 27(7):1461-8. PubMed ID: 23403462
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gene expression profiling and candidate gene resequencing identifies pathways and mutations important for malignant transformation caused by leukemogenic fusion genes.
    Novak RL; Harper DP; Caudell D; Slape C; Beachy SH; Aplan PD
    Exp Hematol; 2012 Dec; 40(12):1016-27. PubMed ID: 22885519
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TET1 plays an essential oncogenic role in MLL-rearranged leukemia.
    Huang H; Jiang X; Li Z; Li Y; Song CX; He C; Sun M; Chen P; Gurbuxani S; Wang J; Hong GM; Elkahloun AG; Arnovitz S; Wang J; Szulwach K; Lin L; Street C; Wunderlich M; Dawlaty M; Neilly MB; Jaenisch R; Yang FC; Mulloy JC; Jin P; Liu PP; Rowley JD; Xu M; He C; Chen J
    Proc Natl Acad Sci U S A; 2013 Jul; 110(29):11994-9. PubMed ID: 23818607
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MLL fusion protein-driven AML is selectively inhibited by targeted disruption of the MLL-PAFc interaction.
    Muntean AG; Chen W; Jones M; Granowicz EM; Maillard I; Hess JL
    Blood; 2013 Sep; 122(11):1914-22. PubMed ID: 23900238
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interaction of MLL amino terminal sequences with menin is required for transformation.
    Caslini C; Yang Z; El-Osta M; Milne TA; Slany RK; Hess JL
    Cancer Res; 2007 Aug; 67(15):7275-83. PubMed ID: 17671196
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.